American pharmaceutical company Amgen (AMGNpokernowclub.US) rose nearly 16% to 322 at the beginning of the sessionpokernowclub.6 dollarspokernowclub, the largest one-day increase since 2009. on the news frontpokernowclubAmgen's mid-term trial of a new weight-loss drug has received positive data, and if the drug is approved, it will compete with Novo Nordisk's Wegovy and Lilly's Zepbound.

pokernowclub|美股异动丨安进大涨近16%，减肥新药中期试验获积极数据

Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.